enow.com Web Search

  1. Ad

    related to: enfortumab vedotin success rate calculator
    • Tips For Caregivers

      Learn How to Better Support Your

      Loved One During Treatment .

    • PADCEV® FAQs

      Find Answers To Common Questions

      About Treatment with PADCEV®.

Search results

  1. Results from the WOW.Com Content Network
  2. Enfortumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Enfortumab_vedotin

    Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

  3. Monomethyl auristatin E - Wikipedia

    en.wikipedia.org/wiki/Monomethyl_auristatin_E

    Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.

  4. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

    www.aol.com/news/seattle-genetics-enfortumab...

    The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

  5. Tisotumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Tisotumab_vedotin

    Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .

  6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

    www.aol.com/news/seagens-sgen-maa-enfortumab...

    The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

  7. Talk:Enfortumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Talk:Enfortumab_vedotin

    Main page; Contents; Current events; Random article; About Wikipedia; Contact us

  8. Rovalpituzumab tesirine - Wikipedia

    en.wikipedia.org/wiki/Rovalpituzumab_tesirine

    Chemical structure of "tesirine" (drawn in black). It consists of a pyrrolobenzodiazepine type dimer (top), which is the actual anti-cancer agent, a Val–Ala structure that can be cleaved by an enzyme to detach the anti-cancer agent from the antibody, a polyethylene glycol spacer, and a maleimide linker which is attached to a cysteine in the antibody's (rovalpituzumab's) peptide backbone ...

  9. Enoblituzumab - Wikipedia

    en.wikipedia.org/wiki/Enoblituzumab

    This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.

  1. Ad

    related to: enfortumab vedotin success rate calculator